Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 21, 2026, 11:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 177 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Vaccines, Pneumococcal Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study Evaluating the Impact of the 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Alaskan Native Children.

NCT00743652
View directory record Official record
Conditions
Pneumococcal Disease, 13-valent Pneumococcal Vaccine
Interventions
13-valent Pneumococcal Conjugate Vaccine
Biological
Lead sponsor
Pfizer
Industry
Eligibility
42 Days to 5 Years
Enrollment
373 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
21
States / cities
Akiak, Alaska • Bethel, Alaska • Chefornak, Alaska + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2012 · Synced Jul 21, 2026, 11:47 AM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Effect of Belimumab on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE)

NCT01597492
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Belimumab plus Early Vaccination, Belimumab plus Late Vaccination
Biological
Lead sponsor
Human Genome Sciences Inc., a GSK Company
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
15
States / cities
Birmingham, Alabama • Paradise Valley, Arizona • Shreveport, Louisiana + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced Jul 21, 2026, 11:47 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older

NCT02045836
View directory record Official record
Conditions
Herpes Zoster, Herpes Zoster Vaccine
Interventions
Herpes Zoster vaccine GSK 1437173A, Licensed pneumococcal polysaccharide conjugate vaccine (23-valent, adsorbed), Pneumovax 23™
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
865 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
3
States / cities
Golden, Colorado • Wichita, Kansas • Columbia, Maryland
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Jul 21, 2026, 11:47 AM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

A Study to Learn About the Safety of an Expanded Pneumococcal Vaccine in Healthy Infants

NCT07573462
View directory record Official record
Conditions
Pneumococcal Disease
Interventions
PG4, 20-valent pneumococcal conjugate vaccine (20vPnC)
Biological
Lead sponsor
Pfizer
Industry
Eligibility
42 Days to 98 Days
Enrollment
2,400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
19
States / cities
Estero, Florida • Fort Lauderdale, Florida • Fort Myers, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Jul 21, 2026, 11:47 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Induction of Cross-protective Antibodies for Serogroup 33 by Pneumococcal Conjugate Vaccines

NCT07135453
View directory record Official record
Conditions
Vaccine, Pneumococcal Disease
Interventions
Pneumococcal Vaccine
Biological
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Jul 21, 2026, 11:47 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Prospective Trial of Vaccine Responses Against Pneumococcus and Influenza in Adult Cancer Patients 65 Years of Age and Older

NCT00741039
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Prostate Cancer
Interventions
inactivated influenza vaccine and the 23- valent pneumococcal vaccine, inactivated influenza vaccine and the PPV23 vaccine (Pneumovax)
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
65 Years and older
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 19, 2015 · Synced Jul 21, 2026, 11:47 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Fever After Simultaneous Versus Sequential Vaccination in Young Children

NCT03165981
View directory record Official record
Conditions
Fever After Vaccination, Fever, Febrile Seizure
Interventions
PCV13, DTaP, IIV
Biological
Lead sponsor
Duke University
Other
Eligibility
12 Months to 16 Months
Enrollment
221 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
3
States / cities
Oakland, California • Atlanta, Georgia • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 17, 2024 · Synced Jul 21, 2026, 11:47 AM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers

Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination

NCT07425392
View directory record Official record
Conditions
Pneumococcal Vaccines
Interventions
31-valent pneumococcal conjugate vaccine, PCV20
Biological
Lead sponsor
Vaxcyte, Inc.
Industry
Eligibility
50 Years and older
Enrollment
752 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
30
States / cities
Chinle, Arizona • Phoenix, Arizona • Whiteriver, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Jul 21, 2026, 11:47 AM EDT
Completed Not applicable Interventional

Pneumococcal Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Receiving Anti-HIV Drugs

NCT00013871
View directory record Official record
Conditions
HIV Infections, Hepatitis B, Measles, Pneumococcal Infections, Pertussis
Interventions
Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed, Measles-Mumps-Rubella Vaccine (Live), Pneumococcal Vaccine, Polyvalent (23-valent), Pneumococcal Conjugate Vaccine, Heptavalent, Hepatitis B Vaccine (Recombinant)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 18 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2004
U.S. locations
38
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Jul 21, 2026, 11:47 AM EDT
Completed Not applicable Interventional

A Study of Thalidomide in HIV-Infected Patients Who Are Receiving HAART

NCT00002392
View directory record Official record
Conditions
HIV Infections
Interventions
Thalidomide
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Jul 21, 2026, 11:47 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Trial of Antibody Responses by Vitamin Supplementation

NCT03859687
View directory record Official record
Conditions
Healthy Participants
Interventions
Vitamin A supplementation, No vitamin A supplementation
Biological
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
1 Year to 4 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Jul 21, 2026, 11:47 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study Evaluating Safety of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Elderly Subjects

NCT00500266
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
13-valent Pneumococcal Conjugate Vaccine (13vPnC)
Biological
Lead sponsor
Pfizer
Industry
Eligibility
68 Years and older
Enrollment
1,053 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
40
States / cities
Chandler, Arizona • Glendale, Arizona • Phoenix, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2011 · Synced Jul 21, 2026, 11:47 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine in Healthy Infants

NCT03512288
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
Multivalent, 13vPnC
Biological
Lead sponsor
Pfizer
Industry
Eligibility
42 Days to 98 Days
Enrollment
460 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
39
States / cities
Fayetteville, Arkansas • Downey, California • Huntington Beach, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2021 · Synced Jul 21, 2026, 11:47 AM EDT
Active, not recruiting No phase listed Observational

A Study to Learn About How Well the Prevnar 20 Vaccine Works for Pneumonia in People Who Are 65 Years and Older

NCT06782282
View directory record Official record
Conditions
Community-Acquired Pneumonia (CAP)
Interventions
Not listed
Lead sponsor
Pfizer
Industry
Eligibility
65 Years and older
Enrollment
22,234,435 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Jul 21, 2026, 11:47 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Trial To Evaluate A Multivalent Pneumococcal Conjugate Vaccine In Healthy Adults 50-85 Years Of Age

NCT03313050
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
Multivalent, Tdap, polysaccharide
Biological
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 85 Years
Enrollment
511 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
18
States / cities
Birmingham, Alabama • Cerritos, California • Savannah, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2020 · Synced Jul 21, 2026, 11:47 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Children With Sickle Cell Disease

NCT00918580
View directory record Official record
Conditions
Pneumococcal Conjugate Vaccine
Interventions
13-valent Pneumoccocal Conjugate Vaccine
Biological
Lead sponsor
Pfizer
Industry
Eligibility
6 Years to 17 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
5
States / cities
Birmingham, Alabama • Louisville, Kentucky • The Bronx, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2014 · Synced Jul 21, 2026, 11:47 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study Evaluating Prevnar Infant Long-term Immune Response Versus Prevnar Naive Cohort

NCT00824850
View directory record Official record
Conditions
Pneumococcal Conjugate Vaccine
Interventions
13-valent Pneumococcal Conjugate Vaccine
Biological
Lead sponsor
Pfizer
Industry
Eligibility
8 Years to 16 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
2
States / cities
Hayward, California • San Jose, California
Source: ClinicalTrials.gov public record
Updated Nov 10, 2011 · Synced Jul 21, 2026, 11:47 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults

NCT03828617
View directory record Official record
Conditions
Pneumococcal Disease
Interventions
20vPnC, 13vPnC
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 49 Years
Enrollment
1,710 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
21
States / cities
Anaheim, California • Sacramento, California • San Jose, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2020 · Synced Jul 21, 2026, 11:47 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study Evaluating the Safety, Tolerability and Immunogenicity of 13vPnC as a 2-Dose Regimen or With 23vPS

NCT00574548
View directory record Official record
Conditions
Pneumococcal Vaccines
Interventions
13 valent Pneumococcal Conjugate Vaccine, 23-valent Pneumococcal Polysaccharide Vaccine
Biological
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
60 Years to 64 Years
Enrollment
720 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
6
States / cities
Chandler, Arizona • Pembroke Pines, Florida • Boise, Idaho + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2011 · Synced Jul 21, 2026, 11:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of a Single Dose of Pneumococcal Whole-Cell Vaccine in Healthy Adults

NCT07059182
View directory record Official record
Conditions
PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE, Prevention of Pneumococcal-induced Acute Otitis Media
Interventions
Inactivated whole-cell Streptococcus pneumoniae vaccine, Placebo
Biological · Drug
Lead sponsor
Serum Life Science Europe GmbH
Industry
Eligibility
18 Years to 49 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Jul 21, 2026, 11:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, Randomized, Controlled, Observer-blinded Trial to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Conjugate Vaccine in Healthy Adults Aged 18 to 49 Years

NCT02955160
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
Multivalent, Tdap
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 49 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Jul 21, 2026, 11:47 AM EDT
Terminated Early Phase 1 Interventional Accepts healthy volunteers Results available

Pneumococcal Conjugate Vaccine in Aging Renal Transplant

NCT03802994
View directory record Official record
Conditions
Renal Transplantation, Aging
Interventions
23 valent pneumococcal polysaccharide vaccine, 13 valent conjugated pneumococcal vaccine, Peripheral blood sample
Drug · Biological · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
35 Years to 75 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
2
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 29, 2021 · Synced Jul 21, 2026, 11:47 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Lots of V114 in Healthy Infants (V114-008)

NCT02987972
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
V114 Lot 1, V114 Lot 2, Prevnar 13™
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
6 Weeks to 12 Weeks
Enrollment
1,051 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
30
States / cities
Birmingham, Alabama • Dothan, Alabama • Jonesboro, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2019 · Synced Jul 21, 2026, 11:47 AM EDT
Terminated Phase 2 Interventional Results available

Lenalidomide in Improving Immune Response to Vaccine Therapy in Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Monoclonal B Cell Lymphocytosis

NCT02309515
View directory record Official record
Conditions
Monoclonal B-Cell Lymphocytosis, Stage 0 Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia, Stage I Small Lymphocytic Lymphoma
Interventions
Laboratory Biomarker Analysis, Lenalidomide, Pneumococcal 13-valent Conjugate Vaccine
Other · Drug · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 18, 2021 · Synced Jul 21, 2026, 11:47 AM EDT